Acne Vulgaris - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 200 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H2 2016, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. The predisposing factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 8, 22, 9, 2, 17 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Acne Vulgaris.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acne Vulgaris Overview 9
Therapeutics Development 10
Pipeline Products for Acne Vulgaris - Overview 10
Pipeline Products for Acne Vulgaris - Comparative Analysis 11
Acne Vulgaris - Therapeutics under Development by Companies 12
Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes 15
Acne Vulgaris - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Acne Vulgaris - Products under Development by Companies 19
Acne Vulgaris - Products under Investigation by Universities/Institutes 23
Acne Vulgaris - Companies Involved in Therapeutics Development 24
3SBio Inc. 24
Allergan Plc 25
Almirall, S.A. 26
Antibiotx ApS 27
Biomar Microbial Technologies 28
BiopharmX, Inc. 29
Braintree Laboratories, Inc. 30
Brickell Biotech, Inc. 31
Cell Medica Limited 32
Cellceutix Corporation 33
Celtaxsys, Inc. 34
Common Pharma Inc 35
Cutanea Life Sciences Inc 36
DermaXon, LLC 37
Dermira Inc. 38
Diffusion Pharmaceuticals Inc. 39
ELORAC, Inc. 40
Ensol Biosciences Inc. 41
Foamix Pharmaceuticals Ltd. 42
Galderma S.A. 43
GlaxoSmithKline Plc 44
Helix BioMedix, Inc. 45
Hovione FarmaCiencia SA 46
Lee's Pharmaceutical Holdings Limited 47
LEO Pharma A/S 48
Novabiotics Limited 49
Novan, Inc. 50
Paratek Pharmaceuticals, Inc. 51
Pfizer Inc. 52
Phosphagenics Limited 53
Photocure ASA 54
Promius Pharma, LLC 55
Provectus Biopharmaceuticals, Inc. 56
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 57
Sol-Gel Technologies Ltd. 58
Sun Pharma Advanced Research Company Ltd. 59
Telesso Technologies Limited 60
Thesan Pharmaceuticals, Inc. 61
Valeant Pharmaceuticals International, Inc. 62
Vectura Group Plc 63
Vyome Biosciences Private Limited 64
XBiotech Inc 65
Xenon Pharmaceuticals Inc. 66
Acne Vulgaris - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 72
Assessment by Route of Administration 75
Assessment by Molecule Type 77
Drug Profiles 79
(adapalene + clindamycin hydrochloride) - Drug Profile 79
(benzoyl peroxide + tretinoin) - Drug Profile 80
(clindamycin phosphate + tretinoin) - Drug Profile 81
A-3APO - Drug Profile 82
acebilustat - Drug Profile 83
Aczone Combo - Drug Profile 86
Aczone X - Drug Profile 87
aminolevulinic acid hydrochloride - Drug Profile 88
AQ-401 - Drug Profile 89
ATx-202 - Drug Profile 90
B-244 - Drug Profile 91
BBI-3000 - Drug Profile 92
benzoyl peroxide - Drug Profile 93
BLI-1100 - Drug Profile 94
botulinum toxinA - Drug Profile 95
brilacidin tetrahydrochloride - Drug Profile 96
CB-0301 - Drug Profile 105
CB-0601 - Drug Profile 108
CLS-007 - Drug Profile 109
dapsone - Drug Profile 110
DFD-10 - Drug Profile 111
DLX-2323 - Drug Profile 112
DLX-2681 - Drug Profile 113
DMT-210 - Drug Profile 114
DRM-01 - Drug Profile 115
DX-0385 - Drug Profile 118
E-10215 - Drug Profile 119
finasteride - Drug Profile 120
FMX-101 - Drug Profile 121
GSK-1940029 - Drug Profile 124
HB-1345 - Drug Profile 125
Hesed-4000 - Drug Profile 126
IB-07A037 - Drug Profile 127
IDP-120 - Drug Profile 128
IDP-121 - Drug Profile 129
IDP-123 - Drug Profile 130
IDP-126 - Drug Profile 131
IDP-129 - Drug Profile 132
IDP-130 - Drug Profile 133
ivermectin - Drug Profile 134
LEO-43204 - Drug Profile 135
LTA-001 - Drug Profile 136
methyl aminolevulinate hydrochloride - Drug Profile 137
minocycline - Drug Profile 139
minocycline - Drug Profile 140
minocycline hydrochloride - Drug Profile 142
MTC-896 - Drug Profile 143
omiganan pentahydrochloride - Drug Profile 144
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 146
PF-06423264 - Drug Profile 147
PH-10 - Drug Profile 148
RA-18C3 - Drug Profile 151
RES-440 - Drug Profile 153
sarecycline hydrochloride - Drug Profile 155
SB-204 - Drug Profile 157
SKP-026 - Drug Profile 160
Small Molecule for Acne and Skin Inflammation - Drug Profile 161
Small Molecules for Acne Vulgaris - Drug Profile 162
Synthetic Peptide for Acne Vulgaris - Drug Profile 163
Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile 164
tazarotene - Drug Profile 165
tretinoin - Drug Profile 166
tretinoin - Drug Profile 167
trifarotene - Drug Profile 168
TSN-2898 - Drug Profile 170
Vaccine for Acne Vulgaris - Drug Profile 171
VB-1953 - Drug Profile 172
XEN-801 - Drug Profile 173
Acne Vulgaris - Dormant Projects 174
Acne Vulgaris - Discontinued Products 181
Acne Vulgaris - Product Development Milestones 182
Featured News & Press Releases 182
Appendix 194
Methodology 194
Coverage 194
Secondary Research 194
Primary Research 194
Expert Panel Validation 194
Contact Us 194
Disclaimer 195

List of Tables

Number of Products under Development for Acne Vulgaris, H2 2016 15
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Development by Companies, H2 2016 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2016 28
Acne Vulgaris - Pipeline by 3SBio Inc., H2 2016 29
Acne Vulgaris - Pipeline by Allergan Plc, H2 2016 30
Acne Vulgaris - Pipeline by Almirall, S.A., H2 2016 31
Acne Vulgaris - Pipeline by Antibiotx ApS, H2 2016 32
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2016 33
Acne Vulgaris - Pipeline by BiopharmX, Inc., H2 2016 34
Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H2 2016 35
Acne Vulgaris - Pipeline by Brickell Biotech, Inc., H2 2016 36
Acne Vulgaris - Pipeline by Cell Medica Limited, H2 2016 37
Acne Vulgaris - Pipeline by Cellceutix Corporation, H2 2016 38
Acne Vulgaris - Pipeline by Celtaxsys, Inc., H2 2016 39
Acne Vulgaris - Pipeline by Common Pharma Inc, H2 2016 40
Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H2 2016 41
Acne Vulgaris - Pipeline by DermaXon, LLC, H2 2016 42
Acne Vulgaris - Pipeline by Dermira Inc., H2 2016 43
Acne Vulgaris - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 44
Acne Vulgaris - Pipeline by ELORAC, Inc., H2 2016 45
Acne Vulgaris - Pipeline by Ensol Biosciences Inc., H2 2016 46
Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 47
Acne Vulgaris - Pipeline by Galderma S.A., H2 2016 48
Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H2 2016 49
Acne Vulgaris - Pipeline by Helix BioMedix, Inc., H2 2016 50
Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2 2016 51
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 52
Acne Vulgaris - Pipeline by LEO Pharma A/S, H2 2016 53
Acne Vulgaris - Pipeline by Novabiotics Limited, H2 2016 54
Acne Vulgaris - Pipeline by Novan, Inc., H2 2016 55
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 56
Acne Vulgaris - Pipeline by Pfizer Inc., H2 2016 57
Acne Vulgaris - Pipeline by Phosphagenics Limited, H2 2016 58
Acne Vulgaris - Pipeline by Photocure ASA, H2 2016 59
Acne Vulgaris - Pipeline by Promius Pharma, LLC, H2 2016 60
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 61
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016 62
Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd., H2 2016 63
Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 64
Acne Vulgaris - Pipeline by Telesso Technologies Limited, H2 2016 65
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 66
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 67
Acne Vulgaris - Pipeline by Vectura Group Plc, H2 2016 68
Acne Vulgaris - Pipeline by Vyome Biosciences Private Limited, H2 2016 69
Acne Vulgaris - Pipeline by XBiotech Inc, H2 2016 70
Acne Vulgaris - Pipeline by Xenon Pharmaceuticals Inc., H2 2016 71
Assessment by Monotherapy Products, H2 2016 72
Assessment by Combination Products, H2 2016 73
Number of Products by Stage and Target, H2 2016 75
Number of Products by Stage and Mechanism of Action, H2 2016 78
Number of Products by Stage and Route of Administration, H2 2016 81
Number of Products by Stage and Molecule Type, H2 2016 83
Acne Vulgaris - Dormant Projects, H2 2016 179
Acne Vulgaris - Dormant Projects (Contd..1), H2 2016 180
Acne Vulgaris - Dormant Projects (Contd..2), H2 2016 181
Acne Vulgaris - Dormant Projects (Contd..3), H2 2016 182
Acne Vulgaris - Dormant Projects (Contd..4), H2 2016 183
Acne Vulgaris - Dormant Projects (Contd..5), H2 2016 184
Acne Vulgaris - Dormant Projects (Contd..6), H2 2016 185
Acne Vulgaris - Discontinued Products, H2 2016 186